- Home
- SLN vs CLLS Comparison
SLN vs CLLS Comparison
Compare SLN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- CLLS
- Stock Information
- Founded
- SLN 1994
- CLLS 1999
- Country
- SLN United Kingdom
- CLLS France
- Employees
- SLN N/A
- CLLS N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- CLLS Health Care
- Exchange
- SLN Nasdaq
- CLLS Nasdaq
- Market Cap
- SLN 345.3M
- CLLS 299.0M
- IPO Year
- SLN N/A
- CLLS 2007
- Fundamental
- Price
- SLN $6.67
- CLLS $5.00
- Analyst Decision
- SLN Buy
- CLLS Buy
- Analyst Count
- SLN 6
- CLLS 1
- Target Price
- SLN $39.67
- CLLS $8.00
- AVG Volume (30 Days)
- SLN 212.8K
- CLLS 125.3K
- Earning Date
- SLN 11-06-2025
- CLLS 11-07-2025
- Dividend Yield
- SLN N/A
- CLLS N/A
- EPS Growth
- SLN N/A
- CLLS N/A
- EPS
- SLN N/A
- CLLS N/A
- Revenue
- SLN $25,830,000.00
- CLLS $82,551,000.00
- Revenue This Year
- SLN N/A
- CLLS N/A
- Revenue Next Year
- SLN N/A
- CLLS $58.00
- P/E Ratio
- SLN N/A
- CLLS N/A
- Revenue Growth
- SLN 40.39
- CLLS 129.04
- 52 Week Low
- SLN $1.97
- CLLS $1.10
- 52 Week High
- SLN $8.88
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- SLN 55.39
- CLLS 68.97
- Support Level
- SLN $5.91
- CLLS $3.90
- Resistance Level
- SLN $6.62
- CLLS $5.35
- Average True Range (ATR)
- SLN 0.51
- CLLS 0.28
- MACD
- SLN -0.05
- CLLS 0.16
- Stochastic Oscillator
- SLN 81.25
- CLLS 86.64
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.